Skip to main content

Table 2 Geometric mean and 95% CI for baseline and year-1 biomarker values and for the year 1 to baseline ratio (change) for cases and controls from the WHI postmenopausal HT trials of estrogen plus progestin (E + P) and estrogen-alone (E-alone)

From: Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases

CHD
  E + P E-alone Difference between cohortsb Overall case vs. control differencec
  Cases Controls P valuea Cases Controls P valuea
N 206 202   152 150    
B2M (mg/mL) N = 206, 141d N = 202, 138d   N = 152, 110d N = 150, 108d    
Baseline 0.13 (0.06, 0.29) 0.11 (0.06, 0.22) <.001 0.13 (0.06, 0.32) 0.12 (0.05, 0.27) 0.05 0.44 0.0001
Year 1 0.15 (0.07, 0.31) 0.13 (0.06, 0.27) 0.01 0.15 (0.06, 0.38) 0.14 (0.07, 0.30) 0.04 0.87 0.003
Change 1.04 (0.51, 2.11) 1.03 (0.55, 1.94) 0.68 1.02 (0.48, 2.17) 1.00 (0.60, 1.67) 0.18 0.69 0.67
ORM1 (mg/mL) N = 204, 139 N = 202, 138   N = 133, 96 N = 150, 108    
Baseline 0.52 (0.27, 1.02) 0.49 (0.27, 0.91) 0.10 0.52 (0.25, 1.08) 0.51 (0.25, 1.02) 0.61 0.52 0.16
Year 1 0.47 (0.24, 0.91) 0.46 (0.22, 0.94) 0.66 0.49 (0.25, 0.96) 0.47 (0.2, 1.08) 0.95 0.97 0.32
Change 0.93 (0.50, 1.71) 0.93 (0.48, 1.78) 0.85 0.93 (0.48, 1.79) 0.91 (0.51, 1.63) 0.41 0.68 0.75
THBS1 (ug/mL) N = 172, 125 N = 175, 124   N = 145, 106 N = 108, 108    
Baseline 1.98 (0.18, 21.35) 2.10 (0.19, 23.82) 0.44 1.85 (0.24, 14.36) 2.36 (0.24, 23.08) 0.02 0.35 0.14
Year 1 1.98 (0.2, 19.12) 2.16 (0.19, 24.55) 0.27 2.16 (0.27, 17.14) 2.39 (0.25, 23) 0.10 0.95 0.38
Change 0.96 (0.12, 7.96) 0.94 (0.13, 6.67) 0.17 1.24 (0.16, 9.53) 0.97 (0.16, 5.76) 0.08 0.26 0.25
CFD (ug/mL) N = 204, 139 N = 202, 138   N = 150, 108 N = 131, 91    
Baseline 0.79 (0.35, 1.74) 0.72 (0.37, 1.4) 0.003 0.78 (0.36, 1.67) 0.76 (0.4, 1.45) 0.22 0.27 0.02
Year 1 0.75 (0.32, 1.73) 0.7 (0.34, 1.42) 0.05 0.81 (0.33, 1.98) 0.77 (0.36, 1.65) 0.20 0.75 0.09
Change 0.98 (0.58, 1.65) 0.96 (0.65, 1.43) 0.26 1.04 (0.63, 1.70) 1.01 (0.72, 1.44) 0.22 0.95 0.30
IGFBP1 (ng/mL) N = 201, 139 N = 201, 138   N = 150, 108 N = 145, 105    
Baseline 10.98 (1.56, 77.48) 10.71 (1.26, 90.8) 0.77 9.21 (1.09, 77.72) 7.61 (0.75, 76.76) 0.19 0.32 0.25
Year 1 15.70 (1.85, 133.37) 15.62 (1.81, 134.43) 0.85 17.67 (1.49, 209.42) 12.52 (0.91, 172.68) 0.06 0.12 0.16
Change 1.63 (0.33, 8.20) 1.40 (0.24, 8.15) 0.41 1.79 (0.37, 8.52) 1.87 (0.27, 12.83) 0.13 0.21 0.38
Stroke
  E + P E-alone Difference between cohorts b Overall case vs. control difference c
  Cases Controls P value a Cases Controls P value a
N 182 176   180 170    
B2M (mg/mL) N = 181, 146d N = 174, 146d   N = 179, 141d N = 170, 134d    
Baseline 0.12 (0.04, 0.38) 0.11 (0.06, 0.20) 0.02 0.13 (0.06, 0.25) 0.11 (0.06, 0.22) 0.002 0.18 0.003
Year 1 0.12 (0.06, 0.26) 0.11 (0.06, 0.21) 0.03 0.13 (0.06, 0.27) 0.12 (0.06, 0.24) 0.06 0.84 0.001
Change 1.05 (0.33, 3.32) 0.99 (0.69, 1.40) 0.32 1.03 (0.64, 1.65) 1.04 (0.70, 1.56) 0.99 0.20 0.31
IGFBP2 (ng/mL) N = 171, 136 N = 169, 139   N = 164, 128 N = 158, 125    
Baseline 80.9 (23.63, 276.99) 73.52 (15.27, 353.91) 0.53 72.55 (16.63, 316.48) 67.38 (15.28, 297.04) 0.36 0.85 0.14
Year 1 64.95 (16.88, 249.86) 66.11 (17.02, 256.78) 0.65 60.57 (12.3, 298.34) 57.99 (12.4, 271.3) 0.63 0.64 0.86
Change 0.85 (0.33, 2.17) 0.90 (0.40, 2.04) 0.42 0.86 (0.34, 2.17) 0.91 (0.32, 2.55) 0.15 0.96 0.16
IGFBP4 (ug/mL) N = 175, 139 N = 170, 139   N = 168, 131 N = 164, 128    
Baseline 0.49 (0.22, 1.08) 0.45 (0.18, 1.09) 0.11 0.48 (0.21, 1.11) 0.43 (0.20, 0.95) 0.03 0.87 0.004
Year 1 0.56 (0.24, 1.35) 0.52 (0.23, 1.16) 0.05 0.57 (0.24, 1.39) 0.5 (0.21, 1.18) 0.01 0.47 0.003
Change 1.05 (0.54, 2.05) 1.05 (0.53, 2.10) 0.76 1.10 (0.59, 2.07) 1.03 (0.55, 1.93) 0.08 0.24 0.59
IGFBP6 (ug/mL) N = 166, 130 N = 159, 133   N = 161, 126 N = 153, 118    
Baseline 0.15 (0.05, 0.43) 0.14 (0.05, 0.4) 0.56 0.15 (0.04, 0.47) 0.14 (0.04, 0.55) 0.99 0.89 0.55
Year 1 0.14 (0.05, 0.41) 0.13 (0.03, 0.51) 0.53 0.14 (0.04, 0.47) 0.14 (0.03, 0.59) 0.58 0.42 0.60
Change 0.92 (0.31, 2.75) 0.91 (0.25, 3.38) 0.99 0.96 (0.28, 3.31) 0.93 (0.33, 2.61) 0.50 0.86 0.57
HPX (mg/mL) N = 175, 140 N = 170, 140   N = 169, 131 N = 164, 128    
Baseline 0.55 (0.33, 0.92) 0.54 (0.31, 0.95) 0.93 0.57 (0.31, 1.06) 0.54 (0.31, 0.97) 0.17 0.42 0.19
Year 1 0.52 (0.33, 0.82) 0.52 (0.31, 0.87) 0.95 0.54 (0.32, 0.9) 0.53 (0.33, 0.83) 0.35 0.78 0.42
Change 1.00 (0.64, 1.58) 0.99 (0.64, 1.51) 0.50 1.02 (0.67, 1.55) 1.04 (0.71, 1.52) 0.71 0.38 0.09
  1. aP value from t-test for log-transformed biomarker values.
  2. bFor the P value between cohorts, a linear regression of log-biomarker value on trial, case versus control status and their interaction was fitted. The reported P value is the P value of the interaction.
  3. cFor the P value of overall difference between cases and controls, a linear regression of log-biomarker value on trial and case versus control status was fitted. The reported P value is the P value of the case versus control variable.
  4. dNumber of women at baseline and 1 year, respectively.
Back to article page

Genome Medicine

ISSN: 1756-994X

Contact us